INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Portfolio Pulse from
Faruqi & Faruqi, LLP is investigating potential securities law violations by Intellia Therapeutics related to its Phase 1/2 study and strategic shifts. The law firm alleges that the company made false or misleading statements about its NTLA-3001 program, which was discontinued in January 2025, resulting in a 15.14% stock price drop.
April 09, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Potential securities lawsuit alleges Intellia misled investors about NTLA-3001 program's viability and research timeline, leading to stock price decline
The lawsuit alleges material misrepresentations about the NTLA-3001 program, which could negatively impact investor confidence and potentially lead to financial penalties
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100